Abstract
Solid-organ transplantation is often the last alternative in many patients with end-stage organ disease. Liver, kidney, heart, and lung transplantation have became standard therapy for selected end-stage diseases, although increasingly potent immunosuppressive agents, surgical techniques, organ preservation, and overall management of transplant recipients have dramatically reduced the incidence of rejection of transplanted organs and improved graft and patient survival. However, infection and malignancy have become major causes of morbidity and mortality following solid organ transplantation. The main reason for infection is related to immuno-suppression, which depresses cell-mediated immunity. The resultant depressed cell-mediated immunity leads to increased susceptibility to intracellular pathogens, such as bacterial, fungal, and herpes viruses, similar to the situation in human immunodeficiency virus (HIV)-infected patients. Otherwise, the presence of metabolic abnormalities, such as protein malnutrition, uremia and hyperglycemia, and the presence of damage to mucocutaneous barriers and foreign bodies that interrupt these barriers, such as intravenous lines, endotracheal tubes, urinary catheters, and chest and biliary tubes, are important factors.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Fishman J A. Infection in solid-organ transplant recipients. N Engl J Med, 2007, 357: 2601–2614.
Avery R K. Prophylactic strategies before solid-organ transplantation. Curr Opin Infect Dis, 2004, 17: 353–356.
Kalil A C, Levitsky J, Lyden E, et al. Meta-analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med, 2005, 143: 870–880.
Hernandez-Hernandez E, Alberu J, Gonzalez-Michaca L, et al. Screening for tuberculosis in the study of the living renal donor in a developing country. Transplantation, 2006, 81: 290–292.
Delmonico F L. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis, 2000, 31: 781–786.
Madayag R M, Johnson L B, Bartlett S T, et al. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation, 1997, 64: 1781–1786.
Abbott K C, Lentine K L, Bucci J R, et al. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant, 2004, 4: 2032–2037.
McCarthy P M, Schmitt S K, Vargo R L, et al. Implantable LVAD infections: implications for permanent use of the device. Ann Thorac Surg, 1996, 61: 359–365; discussion 372–353.
Manuel O, Humar A, Preiksaitis J, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant, 2007, 7: 2797–2801.
Ruiz I, Gavalda J, Monforte V, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant, 2006, 6: 178–182.
Halpern S D, Shaked A, Hasz R D, et al. Informing candidates for solid-organ transplantation about donor risk factors. N Engl J Med, 2008, 358: 2832–2837.
Ahn J, Cohen S M. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl, 2008, 14: 1603–1608.
Eid A J, Razonable R R. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs, 70: 965–981.
Slifkin M, Doron S, Snydman D R. Viral prophylaxis in organ transplant patients. Drugs, 2004, 64: 2763–2792.
Efferth T, Romero M R, Wolf D G, et al. The antiviral activities of artemisinin and artesunate. Clin Infect Dis, 2008, 47: 804–811.
Shapira M Y, Resnick I B, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis, 2008, 46: 1455–1457.
Razonable R R. Immune-based therapies for cytomegalovirus infection. Immunotherapy, 2: 117–130.
Preiksaitis J K. New developments in the diagnosis and management of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clin Infect Dis, 2004, 39: 1016–1023.
Green M, Webber S A. EBV viral load monitoring: unanswered questions. Am J Transplant, 2002, 2: 894–895.
Patel R. Infections in recipients of kidney transplants. Infect Dis Clin North Am, 2001, 15: 901–952, xi.
Smith S R, Butterly D W, Alexander B D, et al. Viral infections after renal transplantation. Am J Kidney Dis, 2001, 37: 659–676.
Johnson S, Gerding D N. Clostridium difficile-associated diarrhea. Clin Infect Dis, 1998, 26: 1027–1034; quiz 1035–1026.
Chavers L S, Moser S A, Benjamin W H, et al. Vancomycin-resistant enterococci: 15 years and counting. J Hosp Infect, 2003, 53: 159–171.
Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med, 2003, 167: 603–662.
el-Agroudy A E, Refaie A F, Moussa O M, et al. Tuberculosis in Egyptian kidney transplant recipients: study of clinical course and outcome. J Nephrol, 2003, 16: 404–411.
Hebert M F, Fisher R M, Marsh C L, et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol, 1999, 39: 91–96.
Singh N. Fungal infections in the recipients of solid organ transplantation. Infect Dis Clin North Am, 2003, 17: 113–134, viii.
Rex J H, Bennett J E, Sugar A M, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med, 1994, 331: 1325–1330.
Rex J H, Pfaller M A, Galgiani J N, et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis, 1997, 24: 235–247.
Patterson J E. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis, 1999, 1: 229–236.
Stevens D A, Kan V L, Judson M A, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis, 2000, 30: 696–709.
Romero A J, Le Pogamp P, Nilsson L G, et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther, 2002, 71: 226–234.
Baden L R, Katz J T, Franck L, et al. Successful toxoplasmosis prophylaxis after orthotopic cardiac transplantation with trimethoprim-sulfamethoxazole. Transplantation, 2003, 75: 339–343.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Zheng, S., Wu, J. (2014). Infectious Microecology in Solid-Organ Transplantation. In: Li, L. (eds) Infectious Microecology. Advanced Topics in Science and Technology in China. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-43883-1_18
Download citation
DOI: https://doi.org/10.1007/978-3-662-43883-1_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-43882-4
Online ISBN: 978-3-662-43883-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)